Home Print this page Email this page Users Online: 278
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
LETTER TO THE EDITOR
Year : 2022  |  Volume : 10  |  Issue : 1  |  Page : 83

Reply to the Letter to the Editor


Department of Emergency Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia

Date of Submission09-Jan-2022
Date of Acceptance09-Jan-2022
Date of Web Publication17-Jan-2022

Correspondence Address:
Mohammed S Alshahrani
Department of Emergency Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province 31952
Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/sjmms.sjmms_17_22

Rights and Permissions

How to cite this article:
Alshahrani MS. Reply to the Letter to the Editor. Saudi J Med Med Sci 2022;10:83

How to cite this URL:
Alshahrani MS. Reply to the Letter to the Editor. Saudi J Med Med Sci [serial online] 2022 [cited 2022 Dec 4];10:83. Available from: https://www.sjmms.net/text.asp?2022/10/1/83/335897



Dear Editor,

We thank Dr. Raghuraman MS for his valuable comments on our manuscript titled “Ketamine for sickle cell vaso-occlusive crises: A systematic review”, and would like to add clarifications.

We do acknowledge that the included studies had substantial heterogeneity in terms of comparative arms, indications for the use, dosage, and groups of patients included, which was also the reason a meta-analysis could not be performed.

The efficacy and safety of ketamine analgesic sub-dissociative dose has been proven in multiple clinical trials, but few such studies included sickle cell disease (SCD) patients with vaso-occlusive painful crises (VOC). The conclusion of our systematic review that inadequate evidence was available to confirm the efficacy and safety of ketamine was only based on that indication. Nonetheless, since the publication of the systematic review, a large randomized trial has been published that assessed the efficacy and safety of ketamine compared to morphine in adult SCD patients with VOC who presented to the emergency department. The primary outcome of this study was the mean difference in the Numerical Pain Rating scale score over 2 h: no difference was noted between the two groups. However, a meaningful pain reduction in the ketamine arm with no increase in drug-related adverse effects, led the authors to conclude that ketamine is an effective analgesic in SCD patients with VOC with a good safety profile.[1]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Alshahrani MS, AlSulaibikh AH, ElTahan MR, AlFaraj SZ, Asonto LP, AlMulhim AA, et al. Ketamine administration for acute painful sickle cell crisis: A randomized controlled trial. Acad Emerg Med. 2021 Aug 27. doi: 10.1111/acem.14382. Online ahead of print.  Back to cited text no. 1
    




 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
   References

 Article Access Statistics
    Viewed1100    
    Printed20    
    Emailed0    
    PDF Downloaded141    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]